Lexicon Pharmaceuticals, Inc. (LXRX) is a fully integrated biopharmaceutical company that is focused on discovering, developing and commercializing breakthrough treatments for diseases with significant unmet medical needs. Founded in 1995 and headquartered in The Woodlands, Texas, the company leverages its proprietary gene knockout technologies to discover novel drug targets.
The mission of Lexicon Pharmaceuticals is to transform the lives of patients by integrating advanced technologies to decode the functions of genes to discover and develop innovative drug therapies. The company has a commitment to novel science and innovative trail design that aims to achieve the broadest impact for patients.
Lexicon Pharmaceuticals has made significant advances in their drug discovery and development programs, with two marketed products. Their first product LX4211 (sotagliflozin), developed as a first-in-class treatment for Type 1 diabetes, was approved by the European Commission in 2019. Their second drug, Xermelo (telotristat ethyl) is used for the treatment of carcinoid syndrome diarrhea in cancer patients with metastatic neuroendocrine tumors and is approved in more than 40 countries.
The company’s drug discovery efforts are supported by a refined genomic approach, which has allowed them to prioritize therapeutic areas with major unmet medical needs, such as diabetes and carcinoid syndrome. This data-driven approach is pivotal in their strategy to advance promising compounds into preclinical and clinical development.
Lexicon Pharmaceuticals invests significantly in research and development, dedicating a major portion of their expenses to it. This affirms their commitment to innovation and continuous expansion of their pipeline. With its dedication to forward-thinking patient-centric solutions, Lexicon Pharmaceuticals has the potential to bring unprecedented change in the lives of patients suffering from serious diseases.
The company has a strong corporate culture that integrates emphasis on technological innovation, strategic development, and a passion for helping patients. Lexicon Pharmaceuticals believes its technology and approach will ensure a steady stream of new products that stand out in the competitive biopharmaceutical market.
A noteworthy aspect of the company is their commitment to leadership ethics, transparency and corporate governance. This is manifested through various policies and procedures that ensure integrity, compliance and credibility in all their dealings.
With its expertise and capabilities, Lexicon Pharmaceuticals is poised to make meaningful contributions to the healthcare industry and ultimately, patient’s lives. This makes LXRX a dynamic entity in the biopharmaceutical sector.